Crinetics Pharmaceuticals, Inc.·4

Mar 3, 4:47 PM ET

Hassard James 4

4 · Crinetics Pharmaceuticals, Inc. · Filed Mar 3, 2023

Insider Transaction Report

Form 4
Period: 2023-03-01
Hassard James
Chief Commercial Officer
Transactions
  • Award

    Common Stock

    2023-03-01+14,00014,000 total
  • Award

    Stock Option (right to buy)

    2023-03-01+65,25065,250 total
    Exercise: $19.64Exp: 2033-02-28Common Stock (65,250 underlying)
Footnotes (2)
  • [F1]The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024.
  • [F2]The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 1, 2023.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION